甘精胰岛素和格列美脲对初诊2型糖尿病疗效的比较

目的对HbA1c〉9％的新诊断的2型糖尿病（T2DM）患者进行甘精胰岛素或格列美脲联合二甲双胍的短期强化治疗，探讨两种强化方案的疗效。方法36例新诊断的T2DM患者随机分为两组，每组18例，分别使用甘精胰岛素或格列美脲联合二甲双胍治疗，疗程12周，对其在治疗前后血糖控制情况及胰岛β细胞功能进行自身及组间比较。结果治疗后两组FPG、2hPG、HbA1c均显著下降（P均〈0．01），HOMA-IR下降（P〈0．05），HOMA-β升高（P〈0．01）。FPG、2hPG、HbA1C治疗前后的差值及治疗12周后早餐前后血糖差值，两组间比较差异均有统计学意义（P均〈0．05），甘精组血糖达标更迅速。结论HbA1c〉9％的新诊断的T2DM患者两种短期强化方案疗效均佳，且胰岛素组降糖更显著、迅速。

The effect of short-term intensive therapy with glargine versus glimepiride in newly diagnosed type 2 diabetic patients

Objective To evaluate the effects of two different short-term intensive therapies on glucose control and β-cell function in newly diagnosed type 2 diabetic patients. Methods The therapeutic effects were measured after intensive therapy in each group. Results After the treatment, FPG,2hPG,HbA1c were significantly decreased（P〈0.01）in each group. HOMA-β were increased（P〈0.01） and HOMA-IR were decreased（P〈0. 05）in each group. The time of achieving optimal glycemic level was shorter and glycemic level was significantly decreased in glargine group. Conclusions The resuls suggest both short-term intensive therapies produce significant effects in newly diagnosed type 2 diabetic patients. Glargine group shows more visible and rapid therapeutic effects.